AP NEWS

Global Moderate Psoriasis Report 2019: API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - ResearchAndMarkets.com

January 30, 2019

DUBLIN--(BUSINESS WIRE)--Jan 30, 2019--The “Moderate Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Moderate Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019″ report provides comprehensive insights about marketed and Phase III products for Moderate Psoriasis . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Moderate Psoriasis

Coverage of API manufacturers for Moderate Psoriasis marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for Moderate Psoriasis

This report provides a comprehensive understanding of the emerging Phase III therapies for Moderate Psoriasis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.

Key Topics Covered:

1. Report Introduction

2. Moderate Psoriasis: Overview

Risk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

Product Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities Product Details United States Europe Global Sales Assessment Historical Global Sales Forecasted Global Sales Patent Details

5. Emerging Therapies (Phase III)

Product Description Research and Development Product Development Activities Forecasted Global Sales Other Phase III profiles

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c6t29d/global_moderate?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190130005314/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Psoriasis Drugs

KEYWORD: EUROPE NORTH AMERICA AFRICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/30/2019 05:47 AM/DISC: 01/30/2019 05:47 AM

http://www.businesswire.com/news/home/20190130005314/en

AP RADIO
Update hourly